Neo-Polycin

Pseudomonas Infections, Otitis Externa, Klebsiella + 15 more

Treatment

9 FDA approvals

20 Active Studies for Neo-Polycin

Treatment for

Pseudomonas Infections

What is Neo-Polycin

Polymyxin B

The Generic name of this drug

Treatment Summary

Polymyxin B is a type of antibiotic used to treat infections caused by gram-negative bacteria. It is typically used to treat urinary tract, meningeal, and bloodstream infections caused by _Pseudomonas aeruginosa_. While it can be effective, it has a narrow therapeutic index and is not usually the first line of treatment. Polymyxin B can also be toxic to the kidneys and nervous system, so it should be used with caution.

Polysporin

is the brand name

image of different drug pills on a surface

Neo-Polycin Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Polysporin

Polymyxin B

1951

279

Approved as Treatment by the FDA

Polymyxin B, commonly known as Polysporin, is approved by the FDA for 9 uses like Meningitis, Bacterial and Conjunctivitis .

Meningitis, Bacterial

Conjunctivitis

Used to treat Ocular Inflammation in combination with Dexamethasone

Ocular Inflammation

Used to treat Ocular Inflammation in combination with Dexamethasone

Bacterial Infections

Urinary Tract Infections

ocular bacterial infections

Used to treat ocular bacterial infections in combination with Bacitracin

Bacteremia caused by Enterobacter aerogenes

Pseudomonas Infections

Urinary Tract Infection (UTI)

Effectiveness

How Neo-Polycin Affects Patients

Polymyxin B is an antibiotic that kills Gram-negative bacteria by disrupting their cell membrane and blocking their ability to breathe. It is usually given through injection for bacterial infections in the urinary tract, meninges, and bloodstream. Polymyxin B does not get absorbed into the body, and it is not changed by metabolic processes after it is excreted.

How Neo-Polycin works in the body

Polymyxin B works by making the outer membrane of Gram negative bacteria more permeable. It does this by forming an electrostatic bond with the negatively charged phosphate groups in the membrane. The bond breaks down the membrane, causing cytoplasmic leakage and killing the cell. Polymyxin B can also bind and neutralize lipopolysaccharides (LPS) that are released during bacterial lysis, preventing reactions to endotoxin. It also disrupts type II NADH-quinone oxidoreductases in the inner membrane, which are essential for respiration. Polymyxin is only effective against common Gram

When to interrupt dosage

The dosage of Neo-Polycin is contingent upon the specified affliction, including Urinary tract infection, Acute Otitis Media (AOM) and Otorrhoea. The quantity of dosage fluctuates as per the delivery technique (e.g. Topical or Suspension / drops - Auricular (otic)) delineated in the table underneath.

Condition

Dosage

Administration

Urinary tract infection

, 100000.0 [USP'U]/mL, 5.0 [USP'U]/mg, 10.0 [USP'U]/mg, 10.0 [iU]/mg, 5.0 [iU]/mg, 200000.0 [USP'U]/mL, 10000.0 [USP'U]/mL, 1.0 [USP'U]/mg, 10000.0 units/mL, 10000.0 mL/mL, 10.0 mg/mg, 10000.0 mg/mL, 500000.0 [iU], 500000.0 [USP'U], 10.0 units/mg, 5000.0 [USP'U], 5.0 units/mg, 5.3228 [iU]/mg, 10000.0 [iU]/mL, 200000.0 [iU]/mL, 0.5 units/mg, 0.0052 mg/mg, 1.0 [iU]/mg, 16250.0 units/mL, 1500.0 units, 50.0 [iU]/mg, 0.01 mg/mg, 0.1 [USP'U]/mg, 10000.0 mg/mg, 50.0 mg, 500000.0 units, 0.77 mg/mL, 5000.0 units/mL, 15.0 [USP'U]/mg, 0.006 mg/mg, 6.0 units/mg, 6000.0 units/mL, 200000.0 units/mL, 1.0 units/mg

Ophthalmic, Solution / drops - Ophthalmic, Topical, Ointment - Topical, , Cream - Topical, Ointment - Ophthalmic, Irrigant - Irrigation, Irrigation, Suspension / drops - Auricular (otic), Auricular (otic), Solution / drops - Auricular (otic), Suspension / drops - Ophthalmic, Suspension - Ophthalmic, Solution - Ophthalmic, Intramuscular; Intrathecal; Intravenous; Ophthalmic, Injection, powder, lyophilized, for solution - Intramuscular; Intrathecal; Intravenous; Ophthalmic, Injection, powder, lyophilized, for solution - Intramuscular; Intravenous, Solution - Irrigation, Stick - Topical, Suspension - Auricular (otic), Powder - Topical, Solution - Auricular (otic), Liquid - Auricular (otic), Cream, Kit, Injection, solution - Intramuscular; Intrathecal; Intravenous; Ophthalmic, Intramuscular; Intrathecal; Intravenous, Intramuscular; Intrathecal; Intravenous; Respiratory (inhalation); Topical, Ointment, Kit - Topical, Liquid - Ophthalmic, Solution / drops, Solution, Suspension, Suspension / drops, Lozenge, Gel - Topical, Liquid, Buccal, Auricular (otic); Ophthalmic, Ointment - Ophthalmic; Topical, Lozenge - Oral, Lozenge - Buccal, Oral, Injection - Intramuscular; Intrathecal; Intravenous, Solution / drops - Auricular (otic); Ophthalmic, Powder, for solution, Injection, powder, lyophilized, for solution, Injection, powder, for solution - Intramuscular; Intrathecal; Intravenous; Ophthalmic, Ointment; Swab - Topical, Intramuscular; Intravenous, Powder, Injection, Injection, powder, for solution, Solution - Auricular (otic); Ophthalmic, Stick, Ophthalmic; Topical, Injection, solution, Powder, for solution - Intramuscular; Intrathecal; Intravenous; Respiratory (inhalation); Topical, Kit - Oral; Topical, Oral; Topical, Gel, Swab - Topical, Ointment; Swab, Suspension - Topical, Powder, for solution - Intramuscular; Intrathecal; Intravenous; Ophthalmic, Swab, Irrigant, Liquid - Auricular (otic); Ophthalmic, Solution - Urethral, Urethral, Injection, powder, lyophilized, for solution - Intramuscular; Intrathecal; Intravenous, Kit - Irrigation; Ophthalmic; Respiratory (inhalation); Topical, Irrigation; Ophthalmic; Respiratory (inhalation); Topical, Kit - Irrigation; Ophthalmic; Topical, Irrigation; Ophthalmic; Topical, Kit - Ophthalmic, Electro-osmosis, Kit - Ophthalmic; Topical, Kit - Electro-osmosis, Kit - Ophthalmic; Respiratory (inhalation); Topical, Ophthalmic; Oral; Respiratory (inhalation); Topical, Kit - Ophthalmic; Oral; Respiratory (inhalation); Topical, Ophthalmic; Respiratory (inhalation); Topical, Kit - Irrigation; Ophthalmic; Oral; Respiratory (inhalation); Topical, Kit - Irrigation; Oral; Respiratory (inhalation); Topical, Irrigation; Oral; Respiratory (inhalation); Topical, Irrigation; Ophthalmic; Oral; Respiratory (inhalation); Topical, Ophthalmic; Oral; Topical, Kit - Ophthalmic; Oral; Topical, Kit - Respiratory (inhalation); Topical, Respiratory (inhalation); Topical, Oral; Respiratory (inhalation); Topical, Kit - Oral; Respiratory (inhalation); Topical, Suspension / drops - Topical, Cream; Kit; Liquid; Ointment; Tablet; Tablet, chewable; Tablet, film coated - Oral; Topical, Cream; Kit; Liquid; Ointment; Tablet; Tablet, chewable; Tablet, film coated

Otitis

Pseudomonas Infections

Klebsiella

Otorrhoea

Urinary Tract Infections

Conjunctivitis, Bacterial

Conjunctivitis

Bacteria

Meningitis, Bacterial

Bacteremia caused by Enterobacter aerogenes

Communicable Diseases

Otitis Externa

Ear Inflammation

Conjunctivitis

Meningitis caused by Haemophilus influenzae

ocular bacterial infections

Urinary Tract Infection (UTI)

Warnings

Neo-Polycin has two known contraindications, so it should not be taken when suffering from the conditions registered in the below table.

Neo-Polycin Contraindications

Condition

Risk Level

Notes

conjunctiva

Do Not Combine

Pulse Frequency

Do Not Combine

There are 20 known major drug interactions with Neo-Polycin.

Common Neo-Polycin Drug Interactions

Drug Name

Risk Level

Description

Vibrio cholerae CVD 103-HgR strain live antigen

Major

The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Polymyxin B.

Naxitamab

Minor

Polymyxin B may increase the neurotoxic activities of Naxitamab.

Typhoid vaccine

Minor

The therapeutic efficacy of Typhoid vaccine can be decreased when used in combination with Polymyxin B.

(R)-warfarin

Moderate

The risk or severity of bleeding can be increased when Polymyxin B is combined with (R)-warfarin.

(S)-Warfarin

Moderate

The risk or severity of bleeding can be increased when Polymyxin B is combined with (S)-Warfarin.

Neo-Polycin Toxicity & Overdose Risk

Taking too much polymyxin B can damage the kidneys and lead to acute kidney injury in up to 39.4% of patients. It can also cause breathing problems, weakness, vertigo, confusion, and other neurological symptoms. Treatment for overdose includes stopping the drug and providing symptomatic care. Mannitol or hemodialysis may be used to manage renal complications. Polymyxin B should be used with extra caution in pregnant women, nursing mothers, kids under 2, and the elderly as safety has not been established in these groups.

image of a doctor in a lab doing drug, clinical research

Neo-Polycin Novel Uses: Which Conditions Have a Clinical Trial Featuring Neo-Polycin?

Currently, there are 46 investigations examining the potential of Neo-Polycin in addressing Klebsiella, Otorrhoea and Pseudomonas Infections.

Condition

Clinical Trials

Trial Phases

Otitis

3 Actively Recruiting

Not Applicable

Urinary Tract Infections

7 Actively Recruiting

Not Applicable, Phase 4

Urinary Tract Infection (UTI)

6 Actively Recruiting

Phase 1, Phase 3, Phase 4, Phase 2

Bacteria

2 Actively Recruiting

Phase 3

Communicable Diseases

0 Actively Recruiting

Meningitis, Bacterial

0 Actively Recruiting

Pseudomonas Infections

0 Actively Recruiting

Otitis Externa

0 Actively Recruiting

ocular bacterial infections

0 Actively Recruiting

Urinary tract infection

0 Actively Recruiting

Conjunctivitis, Bacterial

0 Actively Recruiting

Conjunctivitis

0 Actively Recruiting

Klebsiella

0 Actively Recruiting

Ear Inflammation

0 Actively Recruiting

Meningitis caused by Haemophilus influenzae

0 Actively Recruiting

Conjunctivitis

0 Actively Recruiting

Otorrhoea

0 Actively Recruiting

Bacteremia caused by Enterobacter aerogenes

0 Actively Recruiting

Neo-Polycin Reviews: What are patients saying about Neo-Polycin?

1.3

Patient Review

3/7/2013

Neo-Polycin for Pink Eye from Bacterial Infection

The drops are very irritating and cause a milky white substance to form in your eyes, which is extremely uncomfortable. I never got the full effect of the medication because of this side-effect.

Patient Q&A Section about neo-polycin

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is neo-Polycin used for?

"This medication is used to treat or prevent eye infections caused by bacteria. The active ingredients in this medication (neomycin, bacitracin, and polymyxin) are antibiotics that work by stopping the growth of bacteria. In addition, this medication contains hydrocortisone, which is an anti-inflammatory corticosteroid that works by reducing swelling."

Answered by AI

Is Neo Poly BAC the same as Neosporin?

"Bacitracin and Neosporin are both medicated creams that a person can use directly on their skin. Doctors sometimes call Neosporin “neo-bac-polym” because of the combination of antibiotics that it contains."

Answered by AI

What is neo bacitracin used for?

"This medication is a combination of three antibiotics (neomycin, polymyxin, and bacitracin) and is used to prevent minor skin injuries (such as cuts, scrapes, and burns) from becoming infected. It works by stopping the growth of bacteria."

Answered by AI

What is neo-Polycin?

"Neo-Polycin is an eye ointment used to treat bacterial eye infections. The length of treatment typically lasts 7 to 10 days, depending on the severity of the eye infection. immediately after application of the ointment, Neo-Polycin can cause your vision to be slightly blurry. This medication is available as a generic at a lower cost."

Answered by AI

Clinical Trials for Neo-Polycin

Image of Children's of Alabama in Birmingham, United States.

Antibiotic Duration for Infections in Children

60 - 17

All Sexes

Birmingham, AL

Infections like pneumonia, skin and soft tissue infection (also called SSTI or cellulitis), and urinary tract infections (UTI) are some of the most common reasons children get admitted to the hospital. All three of these conditions require antibiotics for treatment. Although antibiotics are needed to treat the infection and help children feel better, taking them longer than needed can negatively impact children and their families. Negative impacts include things like the burdens of taking more medications and medication side effects. There are guidelines (instructions) from expert medical organizations that suggest the number of days children need antibiotics, but they give a wide range (between 5 and 14 days). Unfortunately, these guidelines are not based on high-quality studies. National data suggests that doctors often choose on the higher end of this range when writing prescriptions for children in the hospital. Our three caregiver co-investigators, other parents of hospitalized children, doctors, other care providers, and researchers, all believe that additional study is needed to determine the best length of antibiotic treatment that weighs both the benefits and harms of antibiotics. The goal of our study is to understand if 5 total days of antibiotic treatment compared to 10 total days of antibiotic treatment is better for children who have been in the hospital for pneumonia, SSTI, or UTI. We will study this question through a randomized control trial. In other words, half of the children will receive 5-days of antibiotics and the other half will receive 10-days of antibiotics. Children in this study (and their caregivers) will not know how many days of antibiotics they will receive to cure their infection because some children will take a placebo (or a pill without antibiotics in it). Only the pharmacy will know if a child is getting antibiotic or placebo (for days 6-10 of treatment). During the first phase of the trial (feasibility phase), 4 hospitals will enroll children in the study. We plan on enrolling 50 patients during this phase. We are starting with just 4 hospitals, so our study team can create and update our study plans if needed. We will closely review information about how many patients and families agree to participate, and if they have any trouble completing any part of the study. We will also interview families to understand the choice to participate in the study, the choice not to participate in the study, and what it is like to be in the study. During the second study phase, we will enroll 1150 more patients across all 11 hospitals. Families will complete short, daily surveys until the 15th day after they started antibiotics, then a larger survey at day 15, at day 20, and at day 30. These surveys will ask about the child's symptoms and recovery from their illness, how the antibiotics are making them feel, and if they had to go back to their doctor, emergency room, or hospital. The answers to these questions will be combined to measure how well the child did, balancing feeling better and having bad effects from the antibiotics. We will use mathematical tests to determine which antibiotic duration is better for treating these illnesses. We will complete other mathematical tests to see if all children should receive the same length of antibiotics or if certain children should be prescribed shorter courses and others longer courses.

Phase 4

Waitlist Available

Drug

Children's of Alabama (+9 Sites)

Sunitha V Kaiser, MD, MSc

Image of Baylor College of Medicine in Houston, United States.

Educational Tool for Urinary Tract Infections

18+

All Sexes

Houston, TX

Urine culture is the most common microbiological test in the outpatient setting in the United States. Unfortunately, contamination during collection is prevalent and undermines test accuracy, leading to incorrect diagnosis, unnecessary treatment, wasted laboratory resources, and inflated costs. Unnecessary antibiotic treatment increases the risk of developing antimicrobial resistance, one of the most serious threats to patients and public health. The goal of this clinical trial is to test whether a bilingual (English and Spanish) educational intervention, an animated video and pictorial flyer, can reduce urine culture contamination and associated inappropriate antibiotic use in adult patients visiting safety-net primary care clinics. The main questions it aims to answer are: 1. Does providing patients with a bilingual educational intervention reduce urine culture contamination rates? 2. Does the intervention lead to fewer unnecessary urinary antibiotic prescriptions? 3. Does providing patients with a bilingual educational intervention reduce contaminated urinalyses? Researchers will compare patients randomized to receive the educational intervention (video and flyer) to those receiving usual care to see if the intervention improves urine collection accuracy and reduces inappropriate antibiotic use. Participants will watch a short, animated video with step-by-step instructions for proper midstream clean-catch urine (MSCC) collection, receive a pictorial flyer (with stills from the video) reinforcing the instructions, and provide a urine sample for culture. Hypothesis: patients who receive the educational intervention will have: lower urine culture contamination rates (primary outcome), fewer urinary antibiotic prescriptions (secondary outcome), and fewer contaminated urinalyses (secondary outcome). The objectives are to (1) develop educational tools: Create an animated video and pictorial flyer with step-by-step urine collection instructions for women and men, developed through an iterative, stakeholder-engaged process, (2) assess acceptability: Use mixed methods (quantitative surveys and qualitative interviews) to evaluate and refine the tools for usability and cultural/linguistic appropriateness, and (3) test effectiveness: Conduct a randomized controlled trial to assess the intervention's impact on urine contamination rates, antibiotic prescribing, and patient satisfaction.

Waitlist Available

Has No Placebo

Baylor College of Medicine

Larissa Grigoryan, MD, PhD